Esophageal Squamous Cell Carcinoma (ESCC) Clinical Trials

17 recruiting

Esophageal Squamous Cell Carcinoma (ESCC) Trials at a Glance

17 actively recruiting trials for esophageal squamous cell carcinoma (escc) are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Shanghai, Paris, and Avignon. Lead sponsors running esophageal squamous cell carcinoma (escc) studies include Sichuan University, Bristol-Myers Squibb, and Beijing Konruns Pharmaceutical Co., Ltd..

Browse esophageal squamous cell carcinoma (escc) trials by phase

Treatments under study

About Esophageal Squamous Cell Carcinoma (ESCC) Clinical Trials

Looking for clinical trials for Esophageal Squamous Cell Carcinoma (ESCC)? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Squamous Cell Carcinoma (ESCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Squamous Cell Carcinoma (ESCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University92 enrolled1 locationNCT07559045
Recruiting
Phase 2

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 3

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Qilu Pharmaceutical Co., Ltd.466 enrolled1 locationNCT07463573
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled7 locationsNCT07085091
Recruiting
Phase 2

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07481058
Recruiting
Phase 2

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien45 enrolled8 locationsNCT07039162
Recruiting
Phase 1

MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Esophageal Cancer, Squamous Cell
UMC Utrecht30 enrolled1 locationNCT07359417
Recruiting
Phase 1

Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)

Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Zhongshan Hospital60 enrolled1 locationNCT07317609
Recruiting
Phase 2

The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital25 enrolled1 locationNCT07290010
Recruiting

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)CholangiocarcinomaHepatocellular Carcinoma (HCC)+3 more
City of Hope Medical Center1,000 enrolled1 locationNCT07224750
Recruiting
Phase 2

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University134 enrolled1 locationNCT06912074
Recruiting

An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Three Gorges Hospital of Chongqing University40 enrolled1 locationNCT07080437
Recruiting

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Gastric AdenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Gastro-esophageal Junction Adenocarcinoma+1 more
Bristol-Myers Squibb500 enrolled2 locationsNCT06504615
Recruiting
Phase 2

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

ImmunotherapyEsophageal Squamous Cell Carcinoma (ESCC)
Sichuan University41 enrolled1 locationNCT06603402
Recruiting

Tumor Regression Grade As Predictor of Adjuvant Therapy

Esophageal Squamous Cell Carcinoma (ESCC)
Fujian Medical University Union Hospital400 enrolled1 locationNCT06710665
Recruiting
Phase 2

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Chest Hospital52 enrolled1 locationNCT06709417
Recruiting
Phase 2

Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)Neoantigen-loaded Dendritic Cell VaccineImmune Checkpoint Inhibitors (ICIs)
Sichuan University165 enrolled1 locationNCT06675201